Cleerly
Cardiac disease AI diagnostics
About
Founded in 2017 by cardiologist James K. Min, MD, in Denver, Cleerly develops AI-driven software that analyzes coronary CT angiography images to precisely quantify and characterize atherosclerosis at sub-millimeter resolution. Its FDA-cleared Cleerly ISCHEMIA product detects the presence or absence of coronary vessel ischemia. Major commercial payers covering 86M+ Americans now provide coverage, including Aetna, UnitedHealthcare, Cigna, Humana, and multiple Blue Cross Blue Shield plans. Medicare approved coverage in November 2024 for approximately 67M beneficiaries. Partners include Viz.ai and Bunkerhill Health.
Products
-
Cleerly Plaque Analysis
— Quantifies and characterizes coronary plaque to assess atherosclerosis and stenosis severity for better CAD diagnosis.
Customer sectors: cardiologists, radiologists, healthcare providers
-
Cleerly ISCHEMIA
— Detects and predicts coronary ischemia non-invasively to improve diagnostic accuracy and prognosis for heart disease patients.
Customer sectors: cardiologists, radiologists, healthcare providers
-
Cleerly COMPARE
— Enables comparative analysis of coronary artery disease metrics over time to assess treatment effectiveness and disease progression.
Customer sectors: cardiologists, healthcare providers
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Cleerly — available to members.
